INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Dec 16, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 240,000 | -- | 398,079 |
Dec 16, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 172,723 | -- | 172,723 |
Nov 14, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 2,313 | -- | 566,324 |
Aug 29, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Other acquisition or disposition | -- | -- | 5,623 |
Aug 28, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 294 | -- | 500,000 |
Aug 28, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 294 | -- | 568,637 |
Aug 27, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,720 | $314.31 | 505,720 |
Aug 27, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 5,116 | $351.33 | 500,604 |
Aug 27, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 310 | $351.33 | 500,294 |
Aug 27, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,720 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.